WHO European Region · country profile

HIV, PrEP and sexual health access in Czechia

Name: HIV medicine, PrEP and sexual health access in Czechia
Creator: SHAPE

Czechia: 88% of verified HIV medicine records are reimbursed; PrEP is available but not reimbursed; sexuality education is classified as restricted. Compare medicines, prevention, reproductive rights and migrant healthcare access, with sources and the date each record was last checked.

Last checked 02/11/2026 · Sources cited on every record

Colour shows the share of verified HIV medicines that are reimbursed.

HIV medicines88% reimbursed28 of 32 verified records PrEPAvailable, not reimbursed1,874 PrEP recipients (2024; UNAIDS GAM)DoxyPEPNot available / no guidelinesNational access and guidance Sexuality educationRestrictedPolicy framework Family planning & abortionRestrictedAbortion law and contraception Migrant healthcare accessWarningEntitlement and practice

10 HIV medicine records for Czechia are still under review. They have not yet been checked against a national source and must not be read as confirmed access or non-access.

Are HIV medicines reimbursed in Czechia?

Of 32 verified HIV medicine records for Czechia, 28 are available and reimbursed (88%), 2 are available but not reimbursed and 2 are not available. 10 further records are still under review.

Reimbursed 28

Biktarvy, Celsentri, Delstrigo, Descovy, Dovato, Edurant, Epivir, Evotaz, Generic TDF/FTC (Emtricitabine/Tenofovir DF), Genvoya, Intelence, Isentress, Juluca, Kaletra and 14 more

Available, not reimbursed 2

Rukobia, Sunlenca

Not available 2

Generic TLD (Tenofovir/Lamivudine/Dolutegravir), Generic TLE (Tenofovir/Lamivudine/Efavirenz)

See every medicine with its source ↓

Is PrEP available and reimbursed in Czechia?

PrEP is available in Czechia, but SHAPE's review did not find it reimbursed.

PrEP recipients: 1,874 PrEP recipients (2024; UNAIDS GAM)

UNAIDS GAM 2025 reports 1,874 people receiving PrEP in 2024. This is a service-use count, not a population coverage percentage, and it does not determine reimbursement. [Source: https://aidsinfo.unaids.org/dataset]

Is DoxyPEP available in Czechia?

SHAPE's review found no national DoxyPEP programme or guideline in Czechia.

No country-specific national DoxyPEP programme was confirmed in this review. WHO's 14 July 2026 guideline conditionally recommends that DoxyPEP may be offered to men who have sex with men and transgender women as part of a comprehensive sexual health package. It prioritizes people with recent or recurrent bacterial STIs and calls for antimicrobial-resistance monitoring; the guideline does not itself establish country-level availability or reimbursement. [Source: https://www.who.int/publications/i/item/9789240124110]

What is the policy on sexuality education in Czechia?

SHAPE classifies the sexuality education framework in Czechia as restricted. This describes the national policy framework, not how every school delivers it.

National framework: Sexuality topics are included in the compulsory health-education framework, but depth, teacher preparation and inclusivity vary by school.
Interpretation: The status summarizes the verified policy framework; it does not guarantee uniform classroom delivery.

[Sources: https://www.unesco.org/gem-report/en/peer ; https://www.who.int/news-room/fact-sheets/detail/comprehensive-sexuality-education ; https://www.bzga-whocc.de/fileadmin/user_upload/Dokumente/BZgA_IPPFEN_ComprehensiveStudyReport_Online.pdf]

What are the rules on abortion and contraception in Czechia?

SHAPE classifies family planning and abortion rights in Czechia as restricted, combining abortion law and contraception policy.

Abortion: Abortion is available on request through 12 weeks, with later access on specified grounds.
Contraception: EPF's 2026 contraception-policy score is 47.3%; the atlas records no national coverage recorded.
Interpretation: The status combines legal rules and national policy access; regional availability and individual eligibility may differ.

[Sources: https://abortion-policies.srhr.org/country/czech-republic/ ; https://www.epfweb.org/sites/default/files/2026-02/CCInfoEU_A3_EN_2026_FEB22-HiRes.pdf]

Can migrants access healthcare in Czechia?

SHAPE's editorial comparison places migrant healthcare access in Czechia in the middle category (Warning). Entitlement: Insurance- and protection-status based; urgent-care floor.

Provider type: Public insurance / contracted providers / NGO · International migrants (2024): 1,025,199

Access rule: Public insurance covers eligible residents and temporary-protection beneficiaries; reception services arrange care for asylum applicants.
Main barriers: Uninsured or undocumented migrants remain dependent on urgent or necessary care, payment and limited NGO support.
Migration measure: UN DESA estimates 1,025,199 international migrants at mid-year 2024. This is a point-in-time stock, not the number of people who arrived during 2024. The estimate is based on the foreign-born population. Refugee, asylum-seeker or refugee-like population data are incorporated where indicated by UN DESA.
Origin definition: The origin shares below use country or area of birth for foreign-born estimates and country of citizenship for foreign-citizen estimates. They do not establish a person's nationality, ethnicity, language, reason for migration, legal status, recent-arrival status or undocumented status.
Measurement basis: Foreign-born population + refugee/asylum adjustments (UN DESA code B R)
Evidence note: ECDC indicators use 2024 reports: the foreign-born share is calculated only among diagnoses with known origin; late diagnosis is the country-level share with CD4 <350 cells/µL and is not migrant-specific. Data Unavailable means no sufficiently interpretable value was published; a blank is not zero. The status is an editorial comparison of legal entitlement and practical access and does not apply equally to every migrant group.

Main origins: Ukraine (50.3%), Slovakia (22.6%), Russian Federation (4.1%)

Selected HIV indicators: Foreign-born HIV Diagnoses (known origin, 2024): 60.6%; Late HIV Diagnosis (CD4 <350, 2024): 47.9%

How Czechia compares

Czechia ranks #9 of 53 countries with enough verified HIV medicine records, by share of records that are reimbursed (88%; median 82%).

0%Marker: median of all countries100%

Neighbouring and nearby countries

Slovakia79%Poland86%Germany92%Austria85%

All HIV medicines in Czechia

Medicine	Active ingredient	Class	Status	Evidence and source	Checked
Biktarvy Gilead Sciences	Bictegravir / Emtricitabine / TAF	INSTI + NRTI/NtRTI	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Celsentri ViiV Healthcare	Maraviroc	Entry Inhibitor	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Delstrigo Merck	Doravirine / Lamivudine / Tenofovir DF	NNRTI + NRTI/NtRTI	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Descovy Gilead Sciences	Emtricitabine / TAF	NRTI	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Dovato ViiV Healthcare	Dolutegravir / Lamivudine	INSTI + NRTI	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Edurant Janssen	Rilpivirine	NNRTI	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Epivir ViiV Healthcare	Lamivudine	NRTI	Reimbursed	Listed on the official national reimbursement list (SUKL Seznam cen a uhrad LP k 1.11.2026). Details: SUKL codes 0026521, 0026519, 0026520; max price 300 mg x30 CZK 1531.93; reimbursement 1697.51. Source: https://sukl.gov.cz/wp-content/uploads/2026/10/SCAU261101v21.txt. Verified 2026-11-02.	02/11/2026
Evotaz Bristol Myers Squibb	Atazanavir / Cobicistat	PI + pharmacokinetic enhancer	Reimbursed	Listed on the official national reimbursement list (SUKL Seznam cen a uhrad LP k 1.11.2026). Details: SUKL 0210925; 300/150 mg x30; CZK 9885.81. Source: https://sukl.gov.cz/wp-content/uploads/2026/10/SCAU261101v21.txt. Verified 2026-11-02.	02/11/2026
Generic TDF/FTC (Emtricitabine/Tenofovir DF) Multiple (Generics)	Emtricitabine / Tenofovir DF	NRTI	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Genvoya Gilead Sciences	Elvitegravir / Cobicistat / Emtricitabine / TAF	INSTI + NRTI/NtRTI + pharmacokinetic enhancer	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Intelence Janssen	Etravirine	NNRTI	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Isentress Merck	Raltegravir	INSTI	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Juluca ViiV Healthcare	Dolutegravir / Rilpivirine	INSTI + NNRTI	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Kaletra AbbVie	Lopinavir / Ritonavir	PI	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Kivexa ViiV Healthcare	Abacavir / Lamivudine	NRTI	Reimbursed	Listed on the official national reimbursement list (SUKL Seznam cen a uhrad LP k 1.11.2026). Details: SUKL 0028383; 600/300 mg x30; CZK 3869.52. Source: https://sukl.gov.cz/wp-content/uploads/2026/10/SCAU261101v21.txt. Verified 2026-11-02.	02/11/2026
Norvir AbbVie	Ritonavir	PI + pharmacokinetic enhancer	Reimbursed	Listed on the official national reimbursement list (SUKL Seznam cen a uhrad LP k 1.11.2026). Details: SUKL 0167417; 100 mg x30; CZK 446.58. Source: https://sukl.gov.cz/wp-content/uploads/2026/10/SCAU261101v21.txt. Verified 2026-11-02.	02/11/2026
Odefsey Gilead Sciences	Rilpivirine / Emtricitabine / TAF	NNRTI + NRTI/NtRTI	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Pifeltro Merck	Doravirine	NNRTI	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Prezista Janssen	Darunavir	PI	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Retrovir ViiV Healthcare	Zidovudine	NRTI	Reimbursed	Listed on the official national reimbursement list (SUKL Seznam cen a uhrad LP k 1.11.2026). Details: SUKL 0237673, 0237674, 0237615, 0242711; 250 mg caps x40 CZK 1477.84. Source: https://sukl.gov.cz/wp-content/uploads/2026/10/SCAU261101v21.txt. Verified 2026-11-02.	02/11/2026
Rezolsta Janssen	Darunavir / Cobicistat	PI + pharmacokinetic enhancer	Reimbursed	Listed on the official national reimbursement list (SUKL Seznam cen a uhrad LP k 1.11.2026). Details: SUKL 0210193; 800/150 mg x30; CZK 9319.05. Source: https://sukl.gov.cz/wp-content/uploads/2026/10/SCAU261101v21.txt. Verified 2026-11-02.	02/11/2026
Symtuza Janssen	Darunavir / Cobicistat / Emtricitabine / TAF	PI + NRTI/NtRTI + pharmacokinetic enhancer	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. EU regulatory update (as of 5 Oct 2026): on 25 June 2026 the CHMP adopted a positive opinion extending the indication, with a new 675/150/200/10 mg tablet strength, to adults and paediatric patients aged 6 years and older weighing at least 25 kg (previously adolescents aged 12 years and older weighing at least 40 kg). European Commission decision not confirmed during this review; national availability and reimbursement of the new strength not verified. [Sources: Local Ministry of Health / ECDC reports; https://www.ema.europa.eu/en/medicines/human/variation/symtuza]	14/09/2026
Tivicay ViiV Healthcare	Dolutegravir	INSTI	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Triumeq ViiV Healthcare	Dolutegravir / Abacavir / Lamivudine	INSTI + NRTI	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Truvada Gilead Sciences	Emtricitabine / Tenofovir DF	NRTI	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Viread Gilead Sciences	Tenofovir DF	NtRTI	Reimbursed	Listed on the official national reimbursement list (SUKL Seznam cen a uhrad LP k 1.11.2026). Details: SUKL 0026960; 245 mg x30; CZK 3987.68. Source: https://sukl.gov.cz/wp-content/uploads/2026/10/SCAU261101v21.txt. Verified 2026-11-02.	02/11/2026
Vocabria ViiV Healthcare	Cabotegravir	INSTI	Reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: Local Ministry of Health / ECDC reports; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121]	14/09/2026
Ziagen ViiV Healthcare	Abacavir	NRTI	Reimbursed	Listed on the official national reimbursement list (SUKL Seznam cen a uhrad LP k 1.11.2026). Details: SUKL 0026863; 300 mg x60; CZK 4914.00. Source: https://sukl.gov.cz/wp-content/uploads/2026/10/SCAU261101v21.txt. Verified 2026-11-02.	02/11/2026
Rukobia ViiV Healthcare	Fostemsavir	Attachment Inhibitor	Available, not reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Sunlenca Gilead Sciences	Lenacapavir	Capsid Inhibitor	Available, not reimbursed	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Generic TLD (Tenofovir/Lamivudine/Dolutegravir) Multiple (Generics)	Tenofovir DF / Lamivudine / Dolutegravir	INSTI + NRTI/NtRTI	Not available	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Generic TLE (Tenofovir/Lamivudine/Efavirenz) Multiple (Generics)	Tenofovir DF / Lamivudine / Efavirenz	NNRTI + NRTI/NtRTI	Not available	Antiretroviral therapy is fully covered by public health insurance for insured patients and is provided through specialised HIV centres across the Czech Republic. Note: Reimbursement applies only to HIV treatment. PrEP or PEP indications are currently not reimbursed. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Apretude ViiV Healthcare	Cabotegravir (PrEP)	INSTI (Long-Acting PrEP)	Under review	Long-acting injectable cabotegravir with oral lead-in tablets, for pre-exposure prophylaxis in adults and adolescents from 12 years weighing at least 35 kg. EMA confirms an EU/EEA-wide marketing authorisation granted by the European Commission on 19 September 2023. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/apretude]	14/09/2026
Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris Viatris Limited	Emtricitabine / Rilpivirine / Tenofovir alafenamide	NNRTI + NRTI/NtRTI	Under review	EMA confirms an EU/EEA-wide marketing authorisation issued on 19 August 2025. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris]	14/09/2026
Emtricitabine / Tenofovir alafenamide Viatris Viatris Limited	Emtricitabine / Tenofovir alafenamide	NRTI/NtRTI	Under review	EMA confirms an EU/EEA-wide marketing authorisation issued on 18 July 2025. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-alafenamide-viatris]	14/09/2026
Emtriva Gilead Sciences	Emtricitabine	NRTI	Under review	Emtricitabine is a nucleoside reverse transcriptase inhibitor used with other antiretroviral medicines for HIV-1 treatment. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtriva]	14/09/2026
Eviplera Gilead Sciences	Rilpivirine / Emtricitabine / Tenofovir DF	NNRTI + NRTI/NtRTI	Under review	A once-daily fixed-dose HIV-1 regimen containing rilpivirine, emtricitabine and tenofovir disoproxil; resistance history and viral-load restrictions apply. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/eviplera]	14/09/2026
Rekambys Janssen	Rilpivirine	Long-Acting NNRTI	Under review	Long-acting injectable rilpivirine used with cabotegravir for maintenance treatment in eligible virologically suppressed patients. The existing Czechia record for the complete Vocabria / Rekambys regimen is classified as 'Review in Progress (2026)', so this required rilpivirine component uses the same access and reimbursement status. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121]	14/09/2026
Reyataz Bristol Myers Squibb	Atazanavir	PI	Under review	EMA confirms an EU/EEA-wide marketing authorisation issued on 2 March 2004. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/reyataz]	14/09/2026
Stribild Gilead Sciences	Elvitegravir / Cobicistat / Emtricitabine / Tenofovir DF	INSTI + NRTI/NtRTI + pharmacokinetic enhancer	Under review	A once-daily fixed-dose HIV-1 regimen containing an integrase inhibitor, pharmacokinetic enhancer and two reverse transcriptase inhibitors. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/stribild]	14/09/2026
Vocabria / Rekambys ViiV Healthcare / Janssen	Cabotegravir / Rilpivirine	Long-Acting ART	Under review	Country-level marketing, supply and reimbursement have not yet been verified. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Source: https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121]	14/09/2026
Yeytuo Gilead Sciences	Lenacapavir (PrEP)	Capsid Inhibitor (Long-Acting PrEP)	Under review	Twice-yearly injectable lenacapavir for pre-exposure prophylaxis; a separate marketing authorisation from Sunlenca, which covers treatment. The European Commission granted an EU/EEA-wide marketing authorisation on 26 August 2025 following accelerated EMA assessment. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/yeytuo]	14/09/2026

Sources

The evidence notes above quote these sources. Each record keeps its own source and last-checked date.

aidsinfo.unaids.org https://aidsinfo.unaids.org/dataset
who.int https://www.who.int/publications/i/item/9789240124110
unesco.org https://www.unesco.org/gem-report/en/peer
who.int https://www.who.int/news-room/fact-sheets/detail/comprehensive-sexua…
bzga-whocc.de https://www.bzga-whocc.de/fileadmin/user_upload/Dokumente/BZgA_IPPFE…
abortion-policies.srhr.org https://abortion-policies.srhr.org/country/czech-republic/
epfweb.org https://www.epfweb.org/sites/default/files/2026-02/CCInfoEU_A3_EN_20…
who.int https://www.who.int/europe/health-topics/refugee-and-migrant-health
ecdc.europa.eu https://www.ecdc.europa.eu/en/publications-data/hivaids-surveillance…
home-affairs.ec.europa.eu https://home-affairs.ec.europa.eu/policies/migration-and-asylum/asyl…
health.ec.europa.eu https://health.ec.europa.eu/social-determinants/migrants-health_en
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/apretude
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-rilp…
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-teno…
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/emtriva
sukl.gov.cz https://sukl.gov.cz/wp-content/uploads/2026/10/SCAU261101v21.txt.
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/eviplera
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys
pharmiweb.com https://www.pharmiweb.com/press-release/2025-01-31/european-commissi…
i-base.info https://i-base.info/htb/50121
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/reyataz
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/stribild
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/variation/symtuza
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/yeytuo

Explore more

HIV medicine map PrEP and DoxyPEP map Reproductive autonomy map Health equity dashboard All countries

This page is for public information and policy discussion and is not medical or legal advice. Found an outdated record or a newer official source? Tell us.